TCIM
SRPT icon

TIAA CREF Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

TIAA CREF Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$24.6M Sell
206,490
-70,134
-25% -$9.02M 0.02% 628
2018
Q4 		$30.2M Sell
276,624
-5,266
-2% -$659K 0.02% 518
2018
Q3 		$45.5M Buy
281,890
+73,792
+35% +$10.1M 0.03% 469
2018
Q2 		$27.5M Buy
208,098
+5,962
+3% +$562K 0.02% 618
2018
Q1 		$15M Buy
202,136
+9,040
+5% +$603K 0.01% 893
2017
Q4 		$10.7M Sell
193,096
-7,996
-4% -$424K 0.01% 1098
2017
Q3 		$9.12M Buy
201,092
+35,003
+21% +$1.4M 0.01% 1213
2017
Q2 		$5.6M Sell
166,089
-33,913
-17% -$1.1M ﹤0.01% 1523
2017
Q1 		$5.92M Sell
200,002
-13,244
-6% -$410K ﹤0.01% 1484
2016
Q4 		$5.85M Sell
213,246
-37,214
-15% -$1.49M ﹤0.01% 1495
2016
Q3 		$15.4K Sell
250,460
-8,422
-3% -$255K 0.01% 883
2016
Q2 		$4.94M Buy
258,882
+42,175
+19% +$781K ﹤0.01% 1543
2016
Q1 		$4.23M Buy
216,707
+11,334
+6% +$198K ﹤0.01% 1611
2015
Q4 		$7.92M Buy
205,373
+7,540
+4% +$244K 0.01% 1217
2015
Q3 		$6.35M Buy
197,833
+225
+0.1% +$7.63K 0.01% 1377
2015
Q2 		$6.01M Sell
197,608
-67,611
-25% -$1.38M ﹤0.01% 1541
2015
Q1 		$3.52M Buy
265,219
+634
+0.2% +$8.45K ﹤0.01% 1867
2014
Q4 		$3.83M Sell
264,585
-7,230
-3% -$122K ﹤0.01% 1819
2014
Q3 		$5.74M Sell
271,815
-3,782
-1% -$85.4K ﹤0.01% 1506
2014
Q2 		$8.21M Buy
275,597
+7,316
+3% +$231K 0.01% 1313
2014
Q1 		$6.45M Buy
268,281
+59,539
+29% +$1.52M ﹤0.01% 1432
2013
Q4 		$4.25M Buy
208,742
+55,839
+37% +$1.66M ﹤0.01% 1756
2013
Q3 		$7.22M Buy
152,903
+24,389
+19% +$939K 0.01% 1312
2013
Q2 		$4.89M Buy
+128,514
New +$4.6M ﹤0.01% 1540

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TIAA CREF Investment Management's SRPT Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Sarepta Therapeutics (SRPT) stake by 25% in Q1 2019, selling an estimated $9.02M and leaving 206,490 shares worth $24.6M. The position accounts for 0.02% of the portfolio, ranked #628.

TIAA CREF Investment Management first reported a position in SRPT in Q2 2013 and has held it in 24 quarters since. The position peaked at $45.5M in Q3 2018. 371 funds tracked by Wall St. Rank hold SRPT as of Q1 2019.

  • TIAA CREF Investment Management held 206,490 shares of Sarepta Therapeutics worth $24.6M as of Q1 2019.
  • TIAA CREF Investment Management sold 70,134 Sarepta Therapeutics shares in Q1 2019, an estimated $9.02M.
  • Sarepta Therapeutics made up 0.02% of TIAA CREF Investment Management's portfolio in Q1 2019, its #628 holding.
  • TIAA CREF Investment Management first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Sarepta Therapeutics position peaked at $45.5M in Q3 2018.
  • 371 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.